Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and will evaluate the safety and tolerability of suvorexant both in participants with impaired renal function and in healthy participants.

Study Design:

This study plans to enroll 16 participants in Part I (8 participants with severe renal impairment and a control group of 8 healthy participants) and 32 participants in Part II (8 participants with moderate renal impairment and a control group of 8 healthy participants; and 8 participants with mild renal impairment and a control group of 8 healthy participants).

Part II will be conducted only if the primary hypothesis is not met in Part I and there is a significant difference in the PK of suvorexant between healthy participants and severe renal impairment participants.

Eligibility Criteria:
Inclusion Criteria:

Impaired Renal Function Participants:

* Females of reproductive potential must have a negative pregnancy test and agree to use (and/or have their partner use) two acceptable methods of birth control
* Body Mass Index (BMI) ≤40 kg/m\^2
* Diagnosis of renal insufficiency

Healthy Participants:

* Females of reproductive potential must have a negative pregnancy test and agree to use (and/or have their partner use) two acceptable methods of birth control
* Body Mass Index (BMI) ≤40 kg/m\^2 and is matched for BMI ± 5 units to his/her corresponding renal participant
* In general good health
* Matched for age ± 10 years to his/her corresponding renal participant

Exclusion Criteria:

Impaired Renal Function Participants:

* Is mentally or legally incapacitated
* History of a clinically significant psychiatric disorder over the last year
* Has rapidly fluctuating renal function or has demonstrated or suspected renal artery stenosis
* Has had a kidney transplant
* Unstable endocrine, gastrointestinal, cardiovascular, hematological, immunological, respiratory, or genitourinary diseases
* History of cancer (Some exceptions apply)
* Regular user of barbiturates or sleep aides
* Consumes excessive amounts of alcohol (\>2 drinks/day)
* Consumes excessive amounts of caffeinated beverages (\>6/day)
* Has had major surgery within 4 weeks
* Has a history of significant multiple and/or severe allergies
* Has a history of cataplexy
* Participant works a night shift and is not able to avoid night shift work during the study
* Current or history of illicit drug abuse
* Nursing mothers

Healthy Participants:

* Is mentally or legally incapacitated;
* Has a history of stroke, chronic seizures, or major neurological disorder
* Unstable endocrine, gastrointestinal, cardiovascular, hematological, immunological, respiratory, or genitourinary diseases
* History of cancer (Some exceptions apply)
* Regular user of barbiturates or sleep aides
* Consumes excessive amounts of alcohol (\>2 drinks/day)
* Consumes excessive amounts of caffeinated beverages (\>6/day)
* Has had major surgery within 4 weeks
* Has a history of significant multiple and/or severe allergies
* Has a history of cataplexy
* Participant works a night shift and is not able to avoid night shift work during the study
* Current or history of illicit drug abuse
* Nursing mothers